0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > LILRB1

LILRB1

Brief Information

Name:Leukocyte immunoglobulin-like receptor B1
Target Synonym:Leukocyte Immunoglobulin Like Receptor B1,LIR-1,MIR-7,ILT2,LIR1,Myeloid Inhibitory Receptor 7,Leucocyte Ig-Like Receptor B1,ILT-2,CD85j Antigen,Ig-Like Transcript 2,PIR-B,Leukocyte Immunoglobulin-Like Receptor, Subfamily B (With TM And ITIM Domains), Memb
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
Cat. No. Species Product Description Structure Purity Feature
CDJ-H82F7 Human Biotinylated Human LILRB1 / CD85j / ILT2 Protein, Fc,Avitag™
CDJ-H82F7-structure
CDJ-H82F7-sds
CDJ-H5252 Human Human LILRB1 / CD85j / ILT2 Protein, Fc Tag
CDJ-H5252-structure
CDJ-H5252-sds

Synonym Name

CD85J,LILRB1,CD85,ILT2,LIR1,MIR7

Background

CD85 antigen-like family member J (CD85J) is also known as Leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1 or LIR-1), Immunoglobulin-like transcript 2 (ILT-2), Monocyte/macrophage immunoglobulin-like receptor 7 (MIR7), which belongs to leukocyte immunoglobulin-like receptor (LIR) family. CD85J / LILRB1 Contains 4 Ig-like C2-type (immunoglobulin-like) domains. CD85J / LIR-1 is expressed predominantly on B-cells and monocytes. CD85J is receptor for class I MHC antigens and recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles and is also receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response. CD85J / LILRB1 interaction with HLA-B or HLA-E leads to inhibition of the signal triggered by FCER1A and inhibits serotonin release. CD85J / LILRB1 inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
BND-22 BND-22 Phase 2 Clinical Biond Biologics Ltd Solid tumours; Neoplasms Details
NGM-707 Phase 2 Clinical Merck & Co, Ngm Biopharmaceuticals Ovarian Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Glioblastoma; Mesothelioma; Cholangiocarcinoma; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details

This web search service is supported by Google Inc.

totop